Investors looking for growth chances often meet the test of weighing a company's expansion possibility against its present cost. The "Growth at a Reasonable Price" (GARP) or "Affordable Growth" method tries to address this by finding companies that are not only expanding well but also trade at prices that do not completely account for that future possibility. This method usually includes looking for stocks with good fundamental condition and earnings to confirm the growth is lasting, paired with a price that allows for increase. One stock that recently appeared through such a careful look is Corcept Therapeutics Inc (NASDAQ:CORT), a commercial-stage pharmaceutical company.
A Focus on Growth and Value
The center of the affordable growth method depends on two parts: clear growth and a fair price. Corcept's fundamental analysis report shows a strong profile on both points. The company gets a Growth rating of 7 out of 10, which is seen as good. This number is supported by good forward-looking estimates, a key part for growth investors.
- Future Growth Estimates: Analysts predict very good growth for Corcept, with earnings per share (EPS) expected to rise by almost 60% each year and sales forecast to grow by more than 22% on average in the next years. This shows a notable quickening from its past results.
- Historical Sales Trend: Backing these predictions, the company has already set a steady record of top-line increase, with sales growing at an average rate of 16.56% over recent years.
On the price side, Corcept gets a rating of 5. While this shows the stock is not deeply low-priced, it is not seen as high-priced either, particularly within its competitive field. The review shows a varied picture:
- Relative Price: Compared to others in the pharmaceuticals industry, Corcept seems fairly priced. Its Price/Earnings (P/E) ratio is lower than about 78% of industry companies, and its Price/Free Cash Flow ratio is better than more than 81% of its rivals.
- Absolute High Price: It is key to see that with a P/E ratio above 50, the stock holds a high price compared to the wider S&P 500 average. However, this high price can be explained by the company's unusual earnings measures and its high expected growth rate, which the price score includes.
The Base: Earnings and Financial Condition
Lasting growth cannot be without a steady operational and financial base. This is why the affordable growth look also requires acceptable scores in earnings and financial condition, rules that Corcept meets with high marks, getting ratings of 8 in both areas.
The company's earnings are a specific strong point. It has very good margins and returns on capital that place it well against industry others.
- High Margins: Corcept keeps a gross margin above 98% and does better than a large majority of its rivals in both profit margin and operating margin.
- Good Returns: Its Return on Assets (11.91%) and Return on Equity (15.38%) are in the top part of the pharmaceuticals industry, showing effective use of investor money.
Financial condition is similarly strong. Corcept works with no debt on its balance sheet, which is an uncommon and positive feature that removes interest cost risk and gives great flexibility.
- Solvency: With an Altman-Z score of 16.71, the company shows no signals of bankruptcy risk and does better than almost 90% of its industry in this key solvency measure.
- Liquidity: The company maintains good liquidity, with current and quick ratios well above 2.5, showing more than enough resources to meet short-term needs.
Analyst Opinions and Market Setting
The fundamental strength of Corcept is mainly fueled by its commercial success with Korlym and its line of next-generation cortisol modulators like relacorilant. Analyst feeling generally shows positive views about its growth path in endocrinology and oncology. It is useful to note that the stock, like many growth-focused names, can show higher ups and downs. The present market setting, with both short and long-term directions for the S&P 500 in negative ground, may push on all stocks, but companies with strong fundamental bases are often in a better place to get through such times.
Conclusion
Corcept Therapeutics offers an example in the affordable growth investment idea. It joins very good expected growth with a price that, while not low in a total sense, is fair relative to its high-quality peer group and its own outlook. This possibility is built on a very steady base of unusual earnings and clean financial condition, having a debt-free balance sheet. For investors carefully looking for companies where growth and value meet, Corcept deserves more study based on these number-based fundamentals.
You can review the complete fundamental breakdown for Corcept Therapeutics here.
Find More Affordable Growth Ideas The look for quality growth stocks at fair prices continues. If you are interested in finding more companies that pass similar strict fundamental filters, you can find them using our set Affordable Growth stock screen.
Disclaimer: This article is for information only and does not make financial advice, a suggestion, or an offer or request to buy or sell any securities. The information shown is based on data given and should not be the only base for any investment choice. Investing includes risk, including the possible loss of principal. Always do your own study and think about talking with a qualified financial advisor before making any investment choices.